Table 1.

SNSCC’s potentially actionable mutations.

Gene	Findings	References	Types of Alterations	Variant Classification of Alterations	Target Drugs (Approved at Least by One Regulatory Agency in Other Cancer Settings)	Principal Treatment Indications
EGFR	≈14% de novo SNSCCC (9/63) ≈77% of ISP-associated SNSCC (17/22)	Udager et al. 2015 [9] Sasaki et al. 2018 [10]	Exon 20ins	Insertion In frame	Amivantamab Mobocertinib	NSCLC
ERBB2	21% (8/38)	Lòpez et al. 2011 [15]	CNG	Amplification	Trastuzumab, Lapatinib, Pertuzumab, Ado-trastuzumab emtansine, Fam-trastuzumab deruxtecan, Margetuximab, Neratinib	Breast cancer, gastric cancer